Clinical trials: Chronic Pruritus
Atopic Dermatitis, Other Pruritic Dermatological
Observational Analytical Validation Study of the Replior ScratchSense
Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life.
- Conditions
- Atopic Dermatitis, Other Pruritic Dermatological, Chronic Pruritus of Unknown Origin
- Trial name
- NCT07909967
- Testing
- Scratch and sleep research tracking
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Replior AB
Hemodialysis Patient, Fatigue
The Effects of an App-based Acupressure on Alleviating Fatigue, Pruritus, and Sleep Quality Among Hemodialysis Patients
Objectives: To evaluate the effectiveness of an app-based self-guided acupressure intervention in alleviating fatigue and pruritus, and in improving sleep quality among hemodialysis patients.
- Trial name
- NCT07259369
- Testing
- app-based acupressure
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07811869
- Testing
- Remibrutinib
- Where
- 10 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Pruritus, Chronic Kidney Diseases
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Rationale: People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.
- Trial name
- NCT06593392
- Testing
- Difelikefalin
- Where
- 18 sites in China, Greece and 5 more
- Volunteers
- 18 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07700056
- Testing
- Remibrutinib
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatic Pruritus, Cholestatic Liver Disease
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis
- Trial name
- NCT07843420
- Testing
- Nemolizumab-ilto
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Chronic Plaque-type Psoriasis
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with…
- Trial name
- NCT07844772
- Testing
- IL-17 Inhibitor Therapy, Conventional Systemic Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Training and Research Hospital
Chronic Pruritus of Unknown Origin
Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin
The goal of this clinical trial is to assess the efficacy and safety of ATTO-1310 in patients with chronic pruritus/itch of unknown origin.
- Trial name
- NCT07833306
- Testing
- ATTO-1310
- Volunteers
- 300 people
- Sponsor
- Attovia Therapeutics Inc
Adverse Event, Peritoneal Dialysis
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
Moderate to severe pruritus significantly impairs the quality of life in peritoneal dialysis patients, and effective treatment options remain limited.
- Conditions
- Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch
- Trial name
- KARE-PD (NCT07098351)
- Testing
- Remitch
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
- Trial name
- NCT06787586
- Testing
- ATTO-1310
- Where
- 17 sites in United States, Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Pruritus Chronic, Kidney Diseases, Chronic
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney…
- Conditions
- Pruritus Chronic, Kidney Diseases, Chronic, Renal Insufficiency, Chronic, Uremia; Chronic
- Trial name
- Anrikefon (NCT07380113)
- Testing
- Anrikefon, Nalfurafine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhujiang Hospital
Chronic Kidney Disease Associated Pruritus, End Stage Renal Disease on Dialysis
Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: A Randomized Controlled Trial
This study evaluates the efficacy and safety of nalfurafine as a treatment for chronic kidney disease-associated pruritus (CKD-aP) in patients undergoing maintenance hemodialysis twice weekly.
- Trial name
- NCT07769073
- Testing
- Nalfurafine Hydrochloride, plasebo
- Volunteers
- 36 people
- Sponsor
- Universitas Indonesia
Chronic Spontaneous Urticaria
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
- Trial name
- BEACON (NCT06162728)
- Testing
- Briquilimab
- Where
- 23 sites in United States, Germany
- Volunteers
- 87 people
- Sponsor
- Jasper Therapeutics, Inc.
Urticaria Chronic
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
- Trial name
- NCT06736262
- Testing
- Briquilimab
- Where
- 19 sites in United States, Germany
- Volunteers
- 67 people
- Sponsor
- Jasper Therapeutics, Inc.
Chronic Pruritus, Eczema
Efficacy of Topical Cannabidiol for Eczema
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life.
- Conditions
- Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis
- Trial name
- NCT06994520
- Testing
- Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Khon Kaen University
Chronic Pruritus of Unknown Origin
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
- Trial name
- CPUO (NCT07074977)
- Testing
- nemolizumab
- Where
- 26 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Pruritus, Chronic Pruritus
Establishment of a Patient Library in Patients With Pruritus Sine Materia
Very little is currently known about the pathophysiology of pruritus sine materia according to the etiology. The creation of this cohort should make it possible to improve our clinical and biological knowledge according to the…
- Conditions
- Pruritus, Chronic Pruritus, Itch
- Trial name
- PRURITHEQUE (NCT05678309)
- Testing
- Blood samples, skin swab sample, skin biopsy sample
- Where
- France
- Volunteers
- 175 people
- Sponsor
- University Hospital, Brest
Chronic Kidney Disease-Associated Pruritus in Hemodialysis
Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis
This is a randomized, open-label, multi-center clinical study aimed at evaluating the efficacy and safety of 12 weeks of nalfurafine hydrochloride administration in the treatment of pruritus in patients undergoing maintenance…
- Trial name
- NCT07650851
- Testing
- Nalfurafine Hydrochloride, Basic treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chinese PLA General Hospital
Chronic Kidney Disease Associated Moderate to Severe Pruritus
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.
- Trial name
- NIKAIA 1 (NCT05075408)
- Testing
- Nemolizumab
- Where
- 64 sites in United States, Hungary and 2 more
- Volunteers
- 258 people
- Sponsor
- Galderma R&D